{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:52:22Z","timestamp":1791406342224,"version":"4.3.3"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ejca.2017.08.014","type":"journal-article","created":{"date-parts":[[2017,9,9]],"date-time":"2017-09-09T06:42:47Z","timestamp":1504939367000},"page":"67-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Challenges and perspectives in the immunotherapy of Hodgkin lymphoma"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-3331","authenticated-orcid":false,"given":"Jean-Marie","family":"Michot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Lazarovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ghez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Danu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Ferm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Bigorgne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Marabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Aspeslagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.08.014_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: a 50-Year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nrclinonc.2012.91","article-title":"State of the art in the treatment of Hodgkin lymphoma","volume":"9","author":"Borchmann","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2141.2011.08713.x","article-title":"Review of the cardiac long-term effects of therapy for Hodgkin lymphoma","volume":"154","author":"Ng","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2017.08.014_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2011.37.1989","article-title":"Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study","volume":"30","author":"van der Kaaij","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib5","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 Years after treatment for Hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.08.014_bib6","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2014-07-537480","article-title":"Perspectives Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma","volume":"125","author":"Connors","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.08.014_bib7","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.radonc.2015.10.022","article-title":"Association of intensity-modulated radiation therapy on overall survival for patients with Hodgkin lymphoma","volume":"118","author":"Parikh","year":"2016","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib9","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2017.08.014_bib10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.1232227","article-title":"Neutralizing tumor-promoting chronic inflammation: amagic bullet?","volume":"339","author":"Coussens","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ejca.2017.08.014_bib11","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2017.08.014_bib12","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2017.08.014_bib13","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating Immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ejca.2017.08.014_bib14","first-page":"0683","article-title":"Rescue of exhausted CD8 T cells by PD-1 \u2013 targeted therapies is CD28-dependent","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejca.2017.08.014_bib15","first-page":"1","article-title":"T cell costimulatory receptor CD28 is a primary target for PD1 mediated inhibition","volume":"1292","author":"Hui","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejca.2017.08.014_bib16","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor Rejection by T Cell receptor ( TCR ) transgenic CD8 + T cells PD-l1\/B7H-1 inhibits the effector phase of tumor Rejection by T Cell receptor","author":"Blank","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2017.08.014_bib17","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: hodgkin and reed-sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be Derived from B Cells at various stages of development","volume":"91","author":"K\u00fcppers","year":"1994","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"10.1016\/j.ejca.2017.08.014_bib18","series-title":"From the *Institute for genetics and $Department of Pathology","first-page":"184","author":"Kanzler","year":"1996"},{"key":"10.1016\/j.ejca.2017.08.014_bib19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.pathol.4.110807.092209","article-title":"Pathogenesis of classical and lymphocyte-predominant hodgkin lymphoma","volume":"4","author":"Schmitz","year":"2009","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"10.1016\/j.ejca.2017.08.014_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin's lymphoma","volume":"9","author":"K\u00fcppers","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2017.08.014_bib21","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-03-704528","article-title":"Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma","author":"Mansouri","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.08.014_bib22","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/blood.V99.4.1474","article-title":"Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma Brief report Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma","volume":"99","author":"Martin Sobero","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.08.014_bib23","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.08.014_bib24","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1038\/sj.onc.1203221","article-title":"Aberrant rel\/nfkb genes and activity in human cancer","volume":"18","author":"Rayet","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2017.08.014_bib25","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1080\/10428190290026259","article-title":"The role of interleukin 13 in classical Hodgkin lymphoma","volume":"43","author":"Skinnider","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2017.08.014_bib26","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2013-06-508044","article-title":"Defining characteristics of classical Hodgkin lymphoma","volume":"122","author":"Greaves","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.08.014_bib27","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2008-07-168096","article-title":"Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome","volume":"113","author":"Chetaille","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.08.014_bib28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ijc.23119","article-title":"Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5\/Rantes in tumor cell growth and microenvironmental interactions","volume":"122","author":"Aldinucci","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2017.08.014_bib29","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0002-9440(10)65424-7","article-title":"High expression of the CC chemokine TARC in reed-sternberg cells","volume":"154","author":"van den Berg","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejca.2017.08.014_bib30","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/asheducation-2014.1.144","article-title":"The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling","volume":"2014","author":"Scott","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.ejca.2017.08.014_bib31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.39.9881","article-title":"Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical hodgkin lymphoma is predictive of outcome","volume":"31","author":"Greaves","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/1471-2407-14-335","article-title":"Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study","volume":"14","author":"Choe","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2017.08.014_bib33","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.918.918","article-title":"A novel anti-lymphoma immune evasion mediated by the interaction between PD-1 enriched NK-cells and CD163+PD-L1+PD-L2+ tumor associated macrophages, that is more prominent in Hodgkin lymphoma than diffuse large B-Cell lymphoma","author":"Gandhi","year":"2016","journal-title":"ASH Abstr Blood J"},{"key":"10.1016\/j.ejca.2017.08.014_bib34","first-page":"3462","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"19","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib35","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-l1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.08.014_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1295202","article-title":"HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune checkpoint inhibitor therapy?","author":"Nijland","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejca.2017.08.014_bib37","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow-sorting and exome sequencing reveals the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"12","author":"Reichel","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.08.014_bib38","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical hodgkin lymphoma with reduced 2M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2017.08.014_bib39","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2006.10.0917","article-title":"HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma","volume":"25","author":"Diepstra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib40","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.08.014_bib41","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","article-title":"Tumor-intrinsic PD-l1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma","volume":"76","author":"Clark","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2017.08.014_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2014.04.003","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis","volume":"92","author":"Roncea","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2017.08.014_bib43","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.08.014_bib44","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.583.583","article-title":"Nivolumab in patients (Pts) with relapsed or refractory classical hodgkin lymphoma (R\/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209\u2013039)","author":"Ansell","year":"2015","journal-title":"Blood ASH Abstr"},{"key":"10.1016\/j.ejca.2017.08.014_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed Death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib47","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3502.3502","article-title":"Outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) after treatment with nivolumab for relapsed\/refractory hodgkin lymphoma","author":"Armand","year":"2016","journal-title":"ASH Abstr Blood J"},{"key":"10.1016\/j.ejca.2017.08.014_bib48","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.08.014_bib49","article-title":"(18)F-FDG PET and CT-scan detect new imaging patterns of response and progression in patients with hodgkin lymphoma treated by anti-PD1 immune checkpoint inhibitor","author":"Dercle","year":"2017","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1016\/j.ejca.2017.08.014_bib50","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.08.014_bib51","article-title":"Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: interim analysis of the AHL2011 Lysa study","author":"Casasnovas","year":"2015","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.ejca.2017.08.014_bib52","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.08.014_bib53","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2017.08.014_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1105.1105","article-title":"Preliminary results from a phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","author":"Herrera","year":"2016","journal-title":"ASH Abstr Blood J"},{"key":"10.1016\/j.ejca.2017.08.014_bib55","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1106.1106","article-title":"A phase I study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research Group (E4412 arms D and E)","author":"Diefenbach","year":"2016","journal-title":"ASH Abstr Blood J"},{"key":"10.1016\/j.ejca.2017.08.014_bib56","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.1998.16.2.584","article-title":"Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant","volume":"16","author":"Little","year":"1998","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fonc.2012.00089","article-title":"Irradiation promotes an m2 macrophage phenotype in tumor hypoxia","volume":"2","author":"Chiang","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib58","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti \u2013 PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2017.08.014_bib59","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","article-title":"A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma","volume":"85","author":"Johnston","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2017.08.014_bib60","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib61","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S1470-2045(11)70265-0","article-title":"Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial","volume":"12","author":"Younes","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib62","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-Cell non-hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib63","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.08.014_bib64","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.505.505","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma (RRMM): Keynote-023","author":"San Miguel","year":"2015","journal-title":"ASH Abstr Blood J"},{"key":"10.1016\/j.ejca.2017.08.014_bib65","first-page":"362","article-title":"Tumor associated macrophages and survival in Hodgkins lymphoma","author":"Steidl","year":"2010","journal-title":"NEJM"},{"key":"10.1016\/j.ejca.2017.08.014_bib66","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2012-04-421057","article-title":"Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial","volume":"120","author":"Tan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.08.014_bib67","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1158\/1078-0432.CCR-14-1845","article-title":"An open-label, multicenter, phase I\/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory Hodgkin lymphoma","volume":"21","author":"von Tresckow","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.08.014_bib68","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2017.08.014_bib69","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2952.2952","article-title":"Strong expression of the immune checkpoint regulators LAG3 and Tim3 in Hodgkin lymphoma","author":"el Halabi","year":"2016","journal-title":"ASH Abstr Blood J"},{"key":"10.1016\/j.ejca.2017.08.014_bib70","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.08.014_bib71","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex\u00a0vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proc Natl Acad Sci U. S. A"},{"issue":"76","key":"10.1016\/j.ejca.2017.08.014_bib72","first-page":"167","article-title":"The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy","volume":"2017","author":"Brochez","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ejca.2017.08.014_bib73","article-title":"Preliminary efficacy from a phase I\/II study of the natural killer cell\u2013targeted antibody lirilumab in combination with nivolumab in squamous cell carcinoma of the head and neck","author":"Leidner","year":"2016","journal-title":"SITC"},{"key":"10.1016\/j.ejca.2017.08.014_bib74","first-page":"641","article-title":"Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease","volume":"47","author":"Alexandrescu","year":"2006","journal-title":"Leuk\u00a0Lymphoma"},{"key":"10.1016\/j.ejca.2017.08.014_bib75","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","article-title":"Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease","volume":"13","author":"Josting","year":"2002","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib76","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.08.014_bib77","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","article-title":"Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study","volume":"34","author":"Santoro","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib78","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2017.08.014_bib79","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/oxfordjournals.annonc.a059242","article-title":"The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease","volume":"6","author":"Ferm\u00e9","year":"1995","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"10.1016\/j.ejca.2017.08.014_bib80","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/bjh.14133","article-title":"Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy","volume":"174","author":"Mart\u00ednez","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2017.08.014_bib81","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1023\/A:1026454831340","article-title":"ESHAP is an active regimen for relapsing Hodgkin's disease","volume":"10","author":"Aparicio","year":"1999","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib82","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib83","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1182\/blood.V93.11.3632","article-title":"ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease","volume":"93","author":"Rodriguez","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.08.014_bib84","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00277-016-2676-0","article-title":"High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma","volume":"95","author":"Aurer","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejca.2017.08.014_bib85","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib86","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hon.2900070109","article-title":"Lomustine, vindesine and bleomycin (LVB) used in the treatment of relapsed advanced Hodgkin's disease. A prospective study on behalf of the East of Scotland and Newcastle Lymphoma Group (ESNLG)","volume":"7","author":"Lennard","year":"1989","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib87","first-page":"1203","volume":"71","author":"Pfreundschuh","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ejca.2017.08.014_bib88","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib89","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.014_bib90","unstructured":"Paper: A Lysa Phase II study of oral JAK1\/2 inhibitor Ruxolitinib in Advanced relapsed\/refractory (R\/R) Hodgkin lymphoma (HL) n.d. https:\/\/ash.confex.com\/ash\/2016\/webprogram\/Paper89589.html. [Accessed 16 July 2017]."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917312066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917312066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T20:32:08Z","timestamp":1719433928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917312066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":90,"alternative-id":["S0959804917312066"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.08.014","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and perspectives in the immunotherapy of Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}